Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lineage Cell Therapeutics (LCTX) Change in Cash (2016 - 2025)

Lineage Cell Therapeutics (LCTX) has 16 years of Change in Cash data on record, last reported at $347000.0 in Q4 2025.

  • For Q4 2025, Change in Cash fell 98.08% year-over-year to $347000.0; the TTM value through Dec 2025 reached -$5.0 million, down 148.54%, while the annual FY2025 figure was -$5.0 million, 148.54% down from the prior year.
  • Change in Cash reached $347000.0 in Q4 2025 per LCTX's latest filing, up from -$1.8 million in the prior quarter.
  • Across five years, Change in Cash topped out at $23.5 million in Q1 2021 and bottomed at -$46.1 million in Q3 2022.
  • Average Change in Cash over 5 years is $504705.9, with a median of $347000.0 recorded in 2025.
  • Peak YoY movement for Change in Cash: surged 7931.74% in 2021, then plummeted 175.71% in 2024.
  • A 5-year view of Change in Cash shows it stood at $23.5 million in 2021, then tumbled by 156.78% to -$13.4 million in 2022, then skyrocketed by 129.88% to $4.0 million in 2023, then soared by 352.1% to $18.0 million in 2024, then plummeted by 98.08% to $347000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Change in Cash were $347000.0 in Q4 2025, -$1.8 million in Q3 2025, and -$5.6 million in Q2 2025.